S-1/A: Spyre Therapeutics Files Amendment to S-1 Registration for Stock Resale
S-1/A Filing
Spyre Therapeutics files an amendment to its S-1 registration statement, covering the resale of up to 12 million shares of common stock by selling stockholders.
Summary
- Spyre Therapeutics filed an S-1/A registration statement with the SEC on March 1, 2024, concerning the resale of common stock by selling stockholders.
- The filing covers up to 6,000,000 shares of common stock and 6,000,000 shares issuable upon conversion of Series B preferred stock.
- The Series B preferred stock was issued in a private placement (December 2023 PIPE) that closed on December 11, 2023.
- Spyre will not receive any proceeds from the sale of these shares.
- The selling stockholders may sell the shares through various methods, including on exchanges, over-the-counter, or in privately negotiated transactions.
- The last reported sale price for Spyre's common stock on February 29, 2024, was $27.44 per share.
- The document emphasizes the high degree of risk associated with investing in Spyre's securities, referencing the 'Risk Factors' section.
- The company is identified as a smaller reporting company, which allows for reduced public company reporting requirements.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It presents factual information without expressing strong positive or negative views.
Risks
- Investing in Spyre's securities involves a high degree of risk, as highlighted in the 'Risk Factors' section of the prospectus.
- The company is a smaller reporting company and is subject to reduced public company reporting requirements.
Future Outlook
The selling stockholders may sell any, all or none of the securities offered by this prospectus and we do not know when or in what amount the Selling Stockholders may sell their Resale Shares hereunder following the effective date of the registration statement of which this prospectus forms a part.
Industry Context
The document does not provide specific details on how this announcement relates to broader industry trends or competitors.
Stakeholder Impact
- The resale of shares may impact the stock price, affecting current shareholders.
- The company will not receive any proceeds from the sale of the Resale Shares offered by the Selling Stockholders under this prospectus.
Next Steps
- The selling stockholders may offer and sell the Resale Shares from time to time pursuant to this prospectus and any accompanying prospectus supplement.
Key Dates
| Date | Description |
|---|---|
| 2015-03-10 | Spyre Therapeutics incorporated as a Delaware corporation |
| 2019-04-30 | Date listed in document |
| 2020-12-31 | Date listed in document |
| 2021-03-21 | Date listed in document |
| 2021-12-31 | Date listed in document |
| 2022-05-01 | Date listed in document |
| 2022-05-31 | Date listed in document |
| 2022-12-31 | Date listed in document |
| 2023-01-01 | Date listed in document |
| 2023-02-28 | Date listed in document |
| 2023-04-30 | Date listed in document |
| 2023-06-22 | Spyre Therapeutics completed the Asset Acquisition |
| 2023-06-30 | Date listed in document |
| 2023-07-07 | Common Stock and Series A Preferred Stock related to the Asset Acquisition were issued to Pre-Merger Spyre stockholders |
| 2023-07-27 | Spyre Therapeutics entered into an agreement to sell the global rights to pegzilarginase to Immedica Pharma AB |
| 2023-08-31 | Date listed in document |
| 2023-09-08 | Spyre Therapeutics effected a reverse stock split of its Common Stock at a ratio of 1-for-25 |
| 2023-09-29 | Date listed in document |
| 2023-09-30 | Date listed in document |
| 2023-11-22 | Date listed in document |
| 2023-11-28 | Aeglea Biotherapeutics, Inc. changed its name to Spyre Therapeutics, Inc. |
| 2023-11-30 | Date listed in document |
| 2023-12-01 | Date listed in document |
| 2023-12-08 | Date listed in document |
| 2023-12-11 | Spyre Therapeutics closed the December 2023 PIPE |
| 2023-12-14 | Date listed in document |
| 2023-12-31 | Date listed in document |
| 2024-02-29 | Last reported sale price for Spyre's common stock was $27.44 per share |
| 2024-03-01 | Date of the prospectus |
Keywords
resale, common stock, preferred stock, registration statement, securities, Spyre Therapeutics, PIPE, selling stockholders
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.